The number of applications that rely on delivery of nucleic acids into cells continues to expand and has become more diverse and complex. Replacing genes, re-programming T cells, producing novel biologics, and silencing mRNA translation, are just some of the noteworthy advances that depend on successful transfection.
That’s why we never stop innovating.
Each of these applications is unique and requires a transfection solution that is intentionally designed to deliver nucleic acid into a variety of cell types – consistently and efficiently.
Since our founding in 1995, we’ve been up to the challenge.
In both the biopharmaceutical and research industries
Published in over 10,000 peer-reviewed publications
Over 1,200 cell lines in which products have been used
56 U.S. and International
patents granted
Since its founding in 1995, Mirus Bio has been meeting industry and customer needs through innovation, collaboration and partnerships.
Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces. This award is based solely on employee feedback collected from a survey administered by an external organization.
Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product portfolio
The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines